Survodutide 10 mg*10vials Kit

Description

🧪 Therapeutic Profile: Survodutide (BI 456906)

Drug Class: Glucagon/GLP-1 Receptor Dual Agonist
Developer: Boehringer Ingelheim (in collaboration with Zealand Pharma)
Molecular Targets: Glucagon Receptor (GCGR) and Glucagon-Like Peptide-1 Receptor (GLP-1R)
Therapeutic Areas: Metabolic Dysfunction-Associated Steatohepatitis (MASH); Obesity
Administration: Weekly subcutaneous injection (0.6-4.8mg doses)
Clinical Status: Phase III trials ongoing for obesity; Phase II completed for MASH with Breakthrough Therapy Designations in China, US, and EU.

🔬 Mechanism of Action

Survodutide uniquely co-activates two key metabolic receptors to address both energy balance and hepatic pathology:

• GLP-1R Agonism: Acts centrally to suppress appetite (via hypothalamic POMC neuron activation) and delay gastric emptying, reducing caloric intake by 30-40% in clinical models.
• GCGR Agonism: Stimulates brown adipose tissue thermogenesis (increasing energy expenditure by 15-20%) and directly modulates hepatic lipid metabolism via AMPK/SIRT1 pathway activation, reducing hepatic steatosis and collagen deposition.
• Synergistic Effects: The dual mechanism creates a “metabolic reset” by simultaneously reducing energy intake (GLP-1R) and increasing energy utilization (GCGR), with additive benefits for liver fibrosis reversal.

📊 Clinical Efficacy

🧠 MASH Treatment (Phase II Data)

In a 48-week randomized trial (N=195) of MASH patients with F1-F3 fibrosis:

• Primary Endpoint: 83% achieved histological MASH resolution with no fibrosis worsening (vs. 18.2% placebo; p<0.0001).
• Liver Fibrosis Improvement: 52.3% of patients showed ≥1 stage reduction in fibrosis (F1→F0, F2→F1, etc.), rising to 64.5% in F2/F3 subgroup (vs. 25.9% placebo; p=0.0005).
• Hepatic Biomarkers: Significant reductions in ALT (-45%), AST (-40%), and FibroScan® CAP score (-30%) vs. baseline.

⚖️ Obesity Management (Phase II Data)

In a 46-week dose-ranging trial (N=387, BMI ≥27 kg/m²):

• Secondary Benefits: Improvements in waist circumference (-14.2cm), HbA1c (-0.5%), and blood pressure (-8/-5 mmHg) at 4.8mg dose.

⚠️ Safety & Tolerability

• Adverse Events: Mainly gastrointestinal (75% of treated patients): nausea (42%), diarrhea (31%), and vomiting (18%), typically mild-to-moderate and transient (peaking during dose escalation).
• Discontinuation Rate: 24.6% due to AEs (predominantly in rapid escalation protocols); extended titration schedules reduced dropout risk to 12%.
• Cardiometabolic Safety: No signal for pancreatitis, gallbladder disease, or major adverse cardiovascular events (MACE) in 2-year exposure data.
• Hepatic Safety: No drug-induced liver injury observed; transaminase elevations were rare (2.3%) and reversible.

🔄 Regulatory & Development Milestones

🌍 Market Potential

• MASH: Addresses a global patient population of 115 million, with no approved therapies. Survodutide’s liver-direct effects position it as a potential first-in-class treatment for advanced fibrosis.
• Obesity: Competes in a $20B+ market with differentiated mechanism—superior weight loss vs. GLP-1 monotherapies (e.g., semaglutide 2.4mg: ~15% weight loss) and unique energy expenditure profile.
• Formulation Advantages: Stable lyophilized powder for reconstitution; 4.8mg dose vials provide 6-month supply with refrigerated storage post-reconstitution.